// App-Quantinova.ai

10518.0 : Tisagenlecleucel (Tisa) for relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL): B2001X study focusing on prior exposure to blinatumomab (BLINA) and inotuzumab (INO).

Researchers

Presenter

  • Joerg Krueger

Principal Investigators

  • Henrique N. S. Bittencourt

  • Susana Rives

  • Andre Baruchel

  • Barbara De Moerloose

  • Christina Peters

  • Peter Bader

  • Jochen Buechner

  • Nicolas Boissel

  • Hidefumi Hiramatsu

  • Karen Thudium

  • Prasanthi Sanjeevi

  • Marina White

  • Lamis K. Eldjerou

  • Adriana Balduzzi

Medical Centers

  • Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

  • Division of Pediatric Hematology-Oncology, Charles-Bruneau Cancer Center, CHU Sainte-Justine, Montreal, QC, Canada

  • Department of Pediatric Hematology and Oncology, Hospital Sant Joan de Deu de Barcelona, Barcelona, Spain

  • Hôpital Universitaire Robert Debré (APHP) and University Paris Diderot,Paris,France

  • Ghent University Hospital, Pediatric Hemato-oncology and Stem Cell Transplantation, Gent, Belgium

  • St. Anna Children s Hospital, Vienna, Austria

  • Division for Stem Cell Transplantation and Immunology, Hospital for Children and Adolescents, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany

  • Department of Pediatric Oncology and Hematology, Essen University Hospital, Essen, Germany

  • Hospital Saint Antoine, Paris, France

  • Department of Gastroenterology, Graduate School of Medicine Kobe University, Kobe, Japan

  • Novartis Institutes for BioMedical Research, East Hanover, NJ

  • Novartis Healthcare Pvt. Ltd, Hyderabad, India

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Clinica Pediatrica - Universita di Milano Bicocca, Monza, Italy

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • tisagenlecleucel-t

  • Blinatumomab

  • Inotuzumab ozogamicin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT03123939

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved